ArticleJournal of market access & health policy2019

Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients.

Daniel C Malone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.